Generalist Engineering is a Liability in Healthcare
The greatest risk in offshore scaling isn’t cost—it’s context. When generalist developers build for high-stakes HLS, a Translation Gap occurs. Clinical nuance is lost, IP becomes fragile, and regulatory friction stalls your time-to-market.
Our AI-Native GCC Solutions eliminate this gap. We place domain-expert practitioners at the head of every engineering vertical, ensuring your science is mastered, not just coded.
Our Solutions
Drug Discovery & Biotech Precision
We build your proprietary Agentic AI Platform for Drug Discovery within your AI-Native HLS GCC. We deploy autonomous agents for Phase I-IV biostatistics, regulatory-grade data architecture, and CSR drafting, governed by veteran biostatisticians to ensure scientific integrity.
MedTech & Surgical Innovation
Your custom Agentic AI Platform for MedTech R&D. Our AI-Native HLS GCC provides engineering pods for robotic surgery and diagnostic AI. We build autonomous surgical logic and MedTech hardware workflows mentored by practicing surgeons to ensure clinical-grade precision.
De-Risk Your Operational Scaling
We do not believe in long-term commitments based on slide decks. We earn trust through The Clinical Catalyst™.
This 90-day implementation phase is designed to stand up a functional Innovation Pod and achieve a specific clinical or commercial milestone. It is a low-friction, high-velocity entry point that allows you to validate our Practitioner-Governed model in real-time.
Phase I
Strategic Intake
Aligning success metrics
and IP boundaries.
Phase II
Pod Deployment
Standing up your practitioner-governed engineering workforce.
From Incubation to 100% Client Ownership
Our Build-Operate-Transfer (BOT) framework ensures you maintain total control over your talent, your data, and your IP.
PHASE I: INCUBATION & ARCHITECTURE
We leverage our clinical networks to recruit domain-native talent and architect a secure, regulatory-compliant environment that mirrors your US/EU headquarters.
PHASE II: PRACTITIONER-LED OPERATIONS
Your team operates under the direct mentorship of our Global Advisory Council. We handle the operational complexity of the India-based entity while you retain full strategic control.
PHASE III: STRATEGIC HANDOVER
Once your hub reaches maturity, we execute a seamless transfer of 100% of the legal entity, talent, and IP. It isn’t a vendor relationship—it’s your people and your 2nd HQ.
Accelerate Multiples for Exit
For Private Equity-backed HLS firms, a Scalanova Health GCC is a primary value-creation lever. By establishing a high-output hub anchored in the Silicon Valley Protocol, portfolio companies reduce R&D burn by 40-60% while accelerating market output—directly enhancing EBITDA and valuation for M&A or IPO exits.